Factors associated with progression to critical illness in 28 days among COVID-19 patients: results from a tertiary care hospital in Istanbul, Turkey
Sili et al.,
Factors associated with progression to critical illness in 28 days among COVID-19 patients: results from a..,
medRxiv, doi:10.1101/2020.10.09.20209775 (Preprint)
Analysis of hospitalized patients in Turkey showing HCQ was given to 99.2% of patients and the incidence of critical illness was lower than most studies. Authors note "whether HCQ administration lowered the rates of critical illness development is beyond the scope of this study." There is no comparison with a control group.
Sili et al., 11 Oct 2020, Turkey, preprint, 21 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.10.09.20209775; this version posted October 11, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .
Factors associated with progression to critical illness in 28 days
among COVID-19 patients: results from a tertiary care hospital in
Istanbul, Turkey
#
Uluhan Sili* , Pinar Ay*, Ahmet Topuzoglu*, Huseyin Bilgin*, Elif Tukenmez Tigen, Buket
Erturk Sengel, Dilek Yagci Caglayik, Baran Balcan, Derya Kocakaya, Sehnaz Olgun Yildizeli,
Fethi Gul, Beliz Bilgili, Rabia Can Sarinoglu, Aysegul Karahasan Yagci, Lutfiye Mulazimoglu
Durmusoglu, Emel Eryuksel, Zekaver Odabasi, Haner Direskeneli, Sait Karakurt, Ismail Cinel,
Volkan Korten
#
* equal contribution
#
corresponding authors
Uluhan Sili, Huseyin Bilgin, Elif Tukenmez Tigen, Buket Erturk Sengel, Dilek Yagci Caglayik,
Lutfiye Mulazimoglu Durmusoglu, Zekaver Odabasi, Volkan Korten, Department of Infectious
Diseases and Clinical Microbiology, Marmara University School of Medicine, Istanbul, Turkey
Pinar Ay, Ahmet Topuzoglu, Department of Public Health, Marmara University School of
Medicine, Istanbul, Turkey
Baran Balcan, Derya Kocakaya, Sehnaz Olgun Yildizeli, Emel Eryuksel, Sait Karakurt,
Department of Pulmonary Medicine, Marmara University School of Medicine, Istanbul,
Turkey
Fethi Gul, Beliz Bilgili, Ismail Cinel, Department of Anesthesiology and Intensive Care,
Marmara University School of Medicine, Istanbul, Turkey
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.10.09.20209775; this version posted October 11, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .
Rabia Can Sarinoglu, Aysegul Karahasan Yagci, Department of Medical Microbiology,
Marmara University School of Medicine, Istanbul, Turkey
Haner Direskeneli, Department of Internal Medicine, Marmara University School of
Medicine, Istanbul, Turkey
Keywords: COVID-19, prospective cohort, critical illness, prognosis
Running title: Critical illness development in COVID-19
Corresponding author: Uluhan Sili, MD, PhD
Address: Department of Infectious Diseases and Clinical Microbiology, Marmara University
School of Medicine, Pendik Training and Research Hospital, 34896, Istanbul, Turkey
Telephone: +90 505 746 5265 (mobile), +90 216 625 4693 (work)
Fax: +90 216 625 4790
E-mail: uluhan@hotmail.com ; uluhan.sili@marmara.edu.tr
Alternate corresponding author: Volkan Korten, MD
Address: Department of Infectious Diseases and Clinical Microbiology, Marmara University
School of Medicine, Pendik Training and Research Hospital, 34896, Istanbul, Turkey
Telephone:
+90 (532) 261 55 58 (mobile), +90 216 625 45 38 (work)
Fax: +90 216 625 4790
E-mail: vkorten@gmail.com ; korten@marmara.edu.tr
2
medRxiv preprint doi: https://doi.org/10.1101/2020.10.09.20209775; this version posted October 11, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit